The FDA has approved Caplyta as adjunctive therapy with antidepressants to treat major depressive disorder in adults, ...

University of Auckland researchers report that an 8-week, twice-weekly LSD microdosing regimen for major depressive disorder ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

To provide some solid data, the authors of the new study gave LSD to a group of patients in New Zealand, and instructed them ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major ...

Among inpatients at an academic center, serial adjunctive ketamine infusions were no more effective at treating major depression than midazolam, according to a randomized clinical trial published in ...

Serial adjunctive ketamine infusions are not more effective than serial midazolam infusions in reducing depressive symptoms.

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...

Creatine supplementation may modestly reduce depressive symptoms, but the effect is small, uncertain, and likely influenced ...

Learn about seasonal affective disorder (SAD) and how to manage the winter blues. Expert tips from Sarah Gagnon on vitamin D, light therapy, and more.